logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Add-on pembrolizumab prevails in early triple-negative breast cancer

Analysis of the first phase 3 trial of pembrolizumab in KEYNOTE-522.